3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
3
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
2
Colonic Neoplasms
2
Triple Negative Breast Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Graft vs Host Disease
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cisplatin
9
pembrolizumab
7
Radiosurgery
6
Gemcitabine
6
Paclitaxel
5
Dexamethasone
5
Taxes
4
Carboplatin
4
trametinib
3
ibrutinib
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Fluorouracil
3
Erlotinib Hydrochloride
3
Blood Specimen Collection
3
Ascorbic Acid
3
venetoclax
2
veliparib
2
tocilizumab
2
pazopanib
2
obinutuzumab
2
naquotinib
2
lenvatinib
2
fludarabine
2
enzalutamide
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms
×
Atorvastatin
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn